-
公开(公告)号：IL242968D0
公开(公告)日：2016-02-01
申请号：IL24296815
申请日：2015-12-06
Applicant: FORENDO PHARMA LTD , ELORANTA MAIRE , HIRVELA LEENA , KANGAS LAURI , KOSKIMIES PASI , LAMMINTAUSTA RISTO , UNKILA MIKKO
Inventor： ELORANTA MAIRE , HIRVELA LEENA , KANGAS LAURI , KOSKIMIES PASI , LAMMINTAUSTA RISTO , UNKILA MIKKO
IPC: C07J20060101
Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.
-
公开(公告)号：IL294140A
公开(公告)日：2022-08-01
申请号：IL29414022
申请日：2022-06-20
Applicant: FORENDO PHARMA LTD , HIRVELA LEENA , HAKOLA MARJO , LINNANEN TERO , KOSKIMIES PASI , STJERNSCHANTZ CAMILLA
Inventor： HIRVELA LEENA , HAKOLA MARJO , LINNANEN TERO , KOSKIMIES PASI , STJERNSCHANTZ CAMILLA
IPC: A61K31/565 , A61K31/58 , A61K45/06 , C07J41/00 , C07J43/00
Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereofwherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.
-
Patent Agency Ranking
公开(公告)号：IL283588D0
公开(公告)日：2021-07-29
申请号：IL28358821
申请日：2021-05-31
Applicant: FORENDO PHARMA LTD , HIRVELA LEENA , HAKOLA MARJO , LINNANEN TERO , KOSKIMIES PASI , STJERNSCHANTZ CAMILLA
Inventor： HIRVELA LEENA , HAKOLA MARJO , LINNANEN TERO , KOSKIMIES PASI , STJERNSCHANTZ CAMILLA
Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereofwherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
-
公开(公告)号：IL271218D0
公开(公告)日：2020-01-30
申请号：IL27121819
申请日：2019-12-05
Applicant: FORENDO PHARMA LTD , HIRVELA LEENA , HAKOLA MARJO , LINNANEN TERO , KOSKIMIES PASI , STJERNSCHANTZ CAMILLA
Inventor： HIRVELA LEENA , HAKOLA MARJO , LINNANEN TERO , KOSKIMIES PASI , STJERNSCHANTZ CAMILLA
IPC: C07J20060101
Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereofwherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.
-
5.发明申请
公开(公告)号：WO2008065100A1
公开(公告)日：2008-06-05
申请号：PCT/EP2007/062856
申请日：2007-11-27
Applicant: SOLVAY PHARMACEUTICALS GMBH , MESSINGER, Josef , HUSEN, Bettina , SCHOEN, Uwe , THOLE, Heinrich-Hubert , KOSKIMIES, Pasi , UNKILA, Mikko
Inventor： MESSINGER, Josef , HUSEN, Bettina , SCHOEN, Uwe , THOLE, Heinrich-Hubert , KOSKIMIES, Pasi , UNKILA, Mikko
IPC: C07J41/00 , C07J43/00 , C07J51/00 , A61K31/565 , A61K31/58 , A61K31/566 , A61P5/32
CPC classification number: C07J51/00 , C07J41/0005 , C07J41/0044 , C07J43/003
Abstract: This invention relates to novel substituted estratrien derivatives of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17- HSD) type 1, type 2 and/or type 3 enzyme, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds.
Abstract translation: 本发明涉及可用于治疗的通式（I）的新型取代的雌三醇衍生物，特别是用于治疗和/或预防需要抑制17β-羟类固醇脱氢酶（17-HSD）1型的类固醇激素依赖性疾病 ，2型和/或3型酶及其盐，含有这些化合物的药物制剂和这些化合物的制备方法。
-
6.发明申请ESTRATRIENE DERIVATIVES AND THEIR USES AS 17BETA-HYDR0XYSTER0ID DEHYDROGENASE INHIBITORS 审中-公开雌二醇衍生物及其作为17BETA-HYDROXYSTER0ID DEHYDROGENASE抑制剂的用途
公开(公告)号：WO2008034796A3
公开(公告)日：2008-07-03
申请号：PCT/EP2007059785
申请日：2007-09-17
Applicant: SOLVAY PHARM GMBH , MESSINGER JOSEF , SCHOEN UWE , HUSEN BETTINA , THOLE HEINRICH-HUBERT , KOSKIMIES PASI , KALLIO LILA
Inventor： MESSINGER JOSEF , SCHOEN UWE , HUSEN BETTINA , THOLE HEINRICH-HUBERT , KOSKIMIES PASI , KALLIO LILA
CPC classification number: C07J43/003
Abstract: This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17ß-hydroxysteroid dehydrogenase (17ß-HSD) such as 17ß-HSD type 1, type 2 or type 3 enzyme.
Abstract translation: 本发明涉及可用于治疗，特别是用于治疗和/或预防类固醇激素依赖性病症，优选类固醇激素依赖性疾病或病症的通式（I）的新颖的雌三醇 - 三唑，其需要抑制17β- 羟基类固醇脱氢酶（17β-HSD），如17β-HSD 1型，2型或3型酶。
-
公开(公告)号：WO2008034796A2
公开(公告)日：2008-03-27
申请号：PCT/EP2007/059785
申请日：2007-09-17
Applicant: SOLVAY PHARMACEUTICALS GMBH , MESSINGER, Josef , SCHOEN, Uwe , HUSEN, Bettina , THOLE, Heinrich-Hubert , KOSKIMIES, Pasi , KALLIO, Lila
Inventor： MESSINGER, Josef , SCHOEN, Uwe , HUSEN, Bettina , THOLE, Heinrich-Hubert , KOSKIMIES, Pasi , KALLIO, Lila
CPC classification number: C07J43/003
Abstract: This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or type 3 enzyme.
Abstract translation: 本发明涉及可用于治疗，特别是用于治疗和/或预防类固醇激素依赖性病症，优选类固醇激素依赖性疾病或病症的通式（I）的新颖的雌三醇 - 三唑，其需要抑制17β- 羟基类固醇脱氢酶（17β-HSD），如17β-HSD 1型，2型或3型酶。
-
-
-
-
-
-
Search Results
7
records
(took 0.025 seconds)
